Oragenics Signs LOI to License CardioDialysis Technology for Neurodegenerative Diseases

Oragenics Inc. (NYSE American: OGEN), a clinical-stage biotechnology company, and Sigyn Therapeutics Inc. (OTCQB: SIGY) have announced the signing of a letter of intent (LOI) under which Oragenics expects to obtain an exclusive license to develop and commercialize Sigyn’s CardioDialysis blood purification technology. The technology is intended for use in traumatic brain injury (TBI) and chronic neurodegenerative diseases, complementing Oragenics’ Phase IIa intranasal neurosteroid candidate ONP-002 in a proposed dual-modality approach targeting inflammation on both sides of the blood-brain barrier.

According to the press release, the CardioDialysis technology is a blood purification system designed to remove inflammatory mediators from the bloodstream. By combining this with ONP-002, which targets inflammation within the brain, Oragenics aims to address neuroinflammation comprehensively. This dual approach could potentially improve outcomes for patients suffering from conditions such as TBI, Parkinson’s disease, Alzheimer’s disease, and other neurological disorders.

Oragenics is currently developing ONP-002 as a potential first-in-class treatment for concussion and mild traumatic brain injury. The company is working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. The intranasal delivery platform used for ONP-002 has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders.

The significance of this announcement lies in the potential to offer a novel therapeutic strategy for conditions with limited treatment options. TBI affects millions worldwide, and chronic neurodegenerative diseases represent a growing public health challenge. By targeting inflammation through both blood purification and intranasal delivery, Oragenics could provide a more effective approach than existing therapies.

For more details on the press release, visit https://ibn.fm/VD4RO. Additional information about Oragenics is available at oragenics.com. The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oragenics Signs LOI to License CardioDialysis Technology for Neurodegenerative Diseases.

The post Oragenics Signs LOI to License CardioDialysis Technology for Neurodegenerative Diseases appeared first on citybuzz.